Perioperative SDD to Prevent Infectious Complications After Esophagectomy

Inclusion Criteria: * Diagnosis of primary esophageal adenocarcinoma or squamous cell carcinoma (cT1b-4a,N0-3,M0) in the mid or distal esophagus or at the level of the gastro-esophageal junction scheduled for undergoing transthoracic esophagectomy with curative intent or for esophageal reconstruction with a gastric or jejunal interposition * Age ≥ 18 years, * Able to give written informed consent. Exclusion Criteria: * Patients planned for rescue surgery, * Patients planned for colonic interposition, * Known or suspected pregnancy, * Patients who have undergone upper GI surgery within 30 days before randomization, * Unable to understand the study information, study instructions and give informed consent. * Patients enrolled in a trial that would interact with the intervention * Patients with a known allergy, sensitivity, or interaction to investigational medicinal product. * Patients with known/documented colonization of Enterobacteriaceae and or Pseudomonas Aeruginosa that are resistant to both tobramycin/gentamicin and to carbapenem antibiotics * Patients undergoing CVVH. * Patients with documented chronic renal failure (GFR \< 15 mls/min) or who are on chronic intermittent hemo- or peritoneal dialysis, * Women of childbearing potential at risk of pregnancy, not using adequate contraception, * Patients with the inability to swallow the SDD * Patients with pre-existing degenerative neuromuscular diseases like, but not limited to, myasthenia gravis or Parkinson disease).